Cardinal Health Stock Hits Record High on Strong Fiscal 2027 Outlook
Earnings James Calloway

Cardinal Health Stock Hits Record High on Strong Fiscal 2027 Outlook

Cardinal Health shares surged to a record high after the company issued a fiscal 2027 earnings forecast that exceeded analyst expectations, driven by strong segment performance.

CAH MCK COR AHCO
Fermi Surges 16% on $6.5B TensorWave Lease, Financing Risks Loom
Markets Daniel Marsh

Fermi Surges 16% on $6.5B TensorWave Lease, Financing Risks Loom

Fermi stock rose 16% after a $6.5B lease with TensorWave, but financing and construction risks persist. Shares remain far below IPO price.

FRMI AMD
AbCellera Surges 34% as Menopause Drug Hits Phase 2 Goals
Analysis Daniel Marsh

AbCellera Surges 34% as Menopause Drug Hits Phase 2 Goals

AbCellera (ABCL) surged 34% after its menopause drug ABCL635 met Phase 2 efficacy endpoints, reducing hot flash frequency and severity with no dropouts.

ABCL SF
eToro Beats Q2 Forecasts, Buys TradeZero for $231M to Expand US Reach
Earnings James Calloway

eToro Beats Q2 Forecasts, Buys TradeZero for $231M to Expand US Reach

eToro exceeded Q2 profit estimates and agreed to acquire TradeZero for up to $231 million, accelerating its US expansion amid shifting trading activity.

ETOR
Sandisk Gets Buy Rating and $1,600 Target Ahead of Investor Day
Earnings James Calloway

Sandisk Gets Buy Rating and $1,600 Target Ahead of Investor Day

Argus Research upgrades Sandisk to Buy with a $1,600 target, citing long-term contracts. Investor Day on Thursday will test the margin trade-off.

SNDK WDC MU
Sionna Plunges 91% as CF Drug Fails Trial, Market Cap Drops Below Cash
Markets Daniel Marsh

Sionna Plunges 91% as CF Drug Fails Trial, Market Cap Drops Below Cash

Sionna shares fell 91% after its CF drug SION-719 failed a Phase 2a trial, with efficacy far below expectations. The stock now trades below cash value.

SION VRTX
Bernstein Lifts Microsoft Target to $660 on Azure Momentum
Analysis Daniel Marsh

Bernstein Lifts Microsoft Target to $660 on Azure Momentum

Bernstein raised its Microsoft price target to $660, citing surging Azure growth and a shift in AI spending risk perception. The stock remains at a discount to historical valuation.

MSFT
Ambiq Q2 Revenue Soars 90%, Supply Constraints Loom
Earnings James Calloway

Ambiq Q2 Revenue Soars 90%, Supply Constraints Loom

Ambiq Micro's Q2 revenue jumped 90% to $33.9M, beating estimates, but supply constraints could limit future growth. Shares rose 6% premarket.

AMBQ
JBS Names New CEO as Q2 Loss Misses Forecasts
Earnings James Calloway

JBS Names New CEO as Q2 Loss Misses Forecasts

JBS posts a surprise $102.1 million Q2 loss and appoints Wesley Batista Filho as CEO, effective January 2027.

JBS PPC
Small Business Optimism Hits 11-Month High, Labor Shortages Persist
Economy Daniel Marsh

Small Business Optimism Hits 11-Month High, Labor Shortages Persist

U.S. small business optimism climbed to an 11-month high in July, but labor shortages and rising borrowing costs could temper growth prospects.

SPY
Apple Faces Downgrade as Jefferies Flags iPhone Margin Risks
Technology Sarah Chen

Apple Faces Downgrade as Jefferies Flags iPhone Margin Risks

Jefferies downgraded Apple to Underperform, cutting its price target to $263.66, citing iPhone margin concerns despite a strong Q3. The stock fell 1.5%.

AAPL JEF KEY UBS HSBC MS
Ouster Expands Utah Lidar Network to Nearly 300 BlueCity Sites
Earnings James Calloway

Ouster Expands Utah Lidar Network to Nearly 300 BlueCity Sites

Ouster (OUST) expands BlueCity lidar in Utah by 160 intersections, approaching 300 sites. Q2 revenue up 56% to $54.6M, though net loss remains.

OUST